Processa Pharmaceuticals (PCSA) Interview: Phase 2 Breast Cancer Data, Pipeline Strategy & FDA Path

In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing ~10x increase in cancer-killing metabolites while maintaining similar side effect severity versus standard capecitabine• How Processa’s approach aims to improve efficacy without increasing toxicity• Details on the formal 20-patient interim analysis evaluating safety and efficacy, expected in 2026• How this program could potentially replace current capecitabine monotherapy in certain breast cancer settings• Insights into the FDA development pathway and dose optimization ahead of a potential pivotal trial🎯 David Young brings over 40 years of experience in chemotherapy drug development, including deep expertise in 5-FU and capecitabine metabolism, which uniquely positions him to lead Processa’s clinical innovation.👉 Processa Pharmaceuticals is a client of RedChip. To learn more about PCSA and to read our full disclosure, visit: PCSAinfo.com.#ProcessaPharmaceuticals #PCSA #BiotechStocks #SmallCapStocks #Oncology #BreastCancerResearch #ClinicalTrials #Phase2Trial #CancerTherapeutics #BiotechInvesting #HealthcareStocks #NASDAQStocks #DrugDevelopment #FDAApproval #LifeSciences #GrowthStocks #InvestorInterview